Single-day famciclovir for the treatment of genital herpes: Follow-up results of time to next recurrence and assessment of antiviral resistance

Neil Bodsworth, Kenneth Fife, William Koltun, Stephen Tyring, Mohammed Abudalu, Mark Prichard, Kamal Hamed

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance. Objectives: To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily). Methods: Longer-term, follow-up data on the time to next recurrence and antiviral sensitivity were collected from a previously reported multicenter, multinational, double-blind, parallel group study in which 1179 immunocompetent adults were randomized 1:1 to receive either single-day famciclovir or 3-day valacyclovir. Treatment was self-initiated within 6 hours of a recurrence. Swabs for viral culture and sensitivity testing were collected for two sequential recurrences. Results: The median time to next recurrence from treatment initiation was 33.5 days for famciclovir and 38.0 days for valacyclovir. No drug resistance to penciclovir, the active metabolite of famciclovir, was observed at baseline nor did any develop by the time of the next recurrence. Limitations: The study had no placebo arm, typing of viral isolates was not performed and viral resistance testing was restricted to penciclovir only. Conclusion: Treatment with single-day famciclovir for recurrent genital herpes did not shorten the time to the next recurrence. Drug resistance to penciclovir continues to be a rare event in immunocompetent patients.

Original languageEnglish
Pages (from-to)483-487
Number of pages5
JournalCurrent Medical Research and Opinion
Volume25
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Herpes Genitalis
Antiviral Agents
valacyclovir
Recurrence
Therapeutics
Drug Resistance
famciclovir
Natural History
Placebos

Keywords

  • Drug resistance
  • Famciclovir
  • Genital herpes
  • Single-day therapy
  • Time to next recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Single-day famciclovir for the treatment of genital herpes : Follow-up results of time to next recurrence and assessment of antiviral resistance. / Bodsworth, Neil; Fife, Kenneth; Koltun, William; Tyring, Stephen; Abudalu, Mohammed; Prichard, Mark; Hamed, Kamal.

In: Current Medical Research and Opinion, Vol. 25, No. 2, 02.2009, p. 483-487.

Research output: Contribution to journalArticle

Bodsworth, Neil ; Fife, Kenneth ; Koltun, William ; Tyring, Stephen ; Abudalu, Mohammed ; Prichard, Mark ; Hamed, Kamal. / Single-day famciclovir for the treatment of genital herpes : Follow-up results of time to next recurrence and assessment of antiviral resistance. In: Current Medical Research and Opinion. 2009 ; Vol. 25, No. 2. pp. 483-487.
@article{5bc06e19ddeb4cc298d1e69e900689b5,
title = "Single-day famciclovir for the treatment of genital herpes: Follow-up results of time to next recurrence and assessment of antiviral resistance",
abstract = "Background: Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance. Objectives: To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily). Methods: Longer-term, follow-up data on the time to next recurrence and antiviral sensitivity were collected from a previously reported multicenter, multinational, double-blind, parallel group study in which 1179 immunocompetent adults were randomized 1:1 to receive either single-day famciclovir or 3-day valacyclovir. Treatment was self-initiated within 6 hours of a recurrence. Swabs for viral culture and sensitivity testing were collected for two sequential recurrences. Results: The median time to next recurrence from treatment initiation was 33.5 days for famciclovir and 38.0 days for valacyclovir. No drug resistance to penciclovir, the active metabolite of famciclovir, was observed at baseline nor did any develop by the time of the next recurrence. Limitations: The study had no placebo arm, typing of viral isolates was not performed and viral resistance testing was restricted to penciclovir only. Conclusion: Treatment with single-day famciclovir for recurrent genital herpes did not shorten the time to the next recurrence. Drug resistance to penciclovir continues to be a rare event in immunocompetent patients.",
keywords = "Drug resistance, Famciclovir, Genital herpes, Single-day therapy, Time to next recurrence",
author = "Neil Bodsworth and Kenneth Fife and William Koltun and Stephen Tyring and Mohammed Abudalu and Mark Prichard and Kamal Hamed",
year = "2009",
month = "2",
doi = "10.1185/03007990802664678",
language = "English",
volume = "25",
pages = "483--487",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Single-day famciclovir for the treatment of genital herpes

T2 - Follow-up results of time to next recurrence and assessment of antiviral resistance

AU - Bodsworth, Neil

AU - Fife, Kenneth

AU - Koltun, William

AU - Tyring, Stephen

AU - Abudalu, Mohammed

AU - Prichard, Mark

AU - Hamed, Kamal

PY - 2009/2

Y1 - 2009/2

N2 - Background: Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance. Objectives: To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily). Methods: Longer-term, follow-up data on the time to next recurrence and antiviral sensitivity were collected from a previously reported multicenter, multinational, double-blind, parallel group study in which 1179 immunocompetent adults were randomized 1:1 to receive either single-day famciclovir or 3-day valacyclovir. Treatment was self-initiated within 6 hours of a recurrence. Swabs for viral culture and sensitivity testing were collected for two sequential recurrences. Results: The median time to next recurrence from treatment initiation was 33.5 days for famciclovir and 38.0 days for valacyclovir. No drug resistance to penciclovir, the active metabolite of famciclovir, was observed at baseline nor did any develop by the time of the next recurrence. Limitations: The study had no placebo arm, typing of viral isolates was not performed and viral resistance testing was restricted to penciclovir only. Conclusion: Treatment with single-day famciclovir for recurrent genital herpes did not shorten the time to the next recurrence. Drug resistance to penciclovir continues to be a rare event in immunocompetent patients.

AB - Background: Episodic therapy of genital herpes is usually recommended for patients with infrequent symptomatic recurrences and where transmission is not a concern. While shorter courses are as effective as standard 5-day regimens, it is unknown whether abbreviated therapy has detrimental effects on natural history and the development of antiviral resistance. Objectives: To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily). Methods: Longer-term, follow-up data on the time to next recurrence and antiviral sensitivity were collected from a previously reported multicenter, multinational, double-blind, parallel group study in which 1179 immunocompetent adults were randomized 1:1 to receive either single-day famciclovir or 3-day valacyclovir. Treatment was self-initiated within 6 hours of a recurrence. Swabs for viral culture and sensitivity testing were collected for two sequential recurrences. Results: The median time to next recurrence from treatment initiation was 33.5 days for famciclovir and 38.0 days for valacyclovir. No drug resistance to penciclovir, the active metabolite of famciclovir, was observed at baseline nor did any develop by the time of the next recurrence. Limitations: The study had no placebo arm, typing of viral isolates was not performed and viral resistance testing was restricted to penciclovir only. Conclusion: Treatment with single-day famciclovir for recurrent genital herpes did not shorten the time to the next recurrence. Drug resistance to penciclovir continues to be a rare event in immunocompetent patients.

KW - Drug resistance

KW - Famciclovir

KW - Genital herpes

KW - Single-day therapy

KW - Time to next recurrence

UR - http://www.scopus.com/inward/record.url?scp=64249169947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249169947&partnerID=8YFLogxK

U2 - 10.1185/03007990802664678

DO - 10.1185/03007990802664678

M3 - Article

C2 - 19192993

AN - SCOPUS:64249169947

VL - 25

SP - 483

EP - 487

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -